--- title: Insights --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) # Insights ## See our event recap Filter by tags [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Oral solid dosage form](https://content.siegfried.ch/insights/tag/oral-solid-dosage-form) [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Oral solid dosage form](https://content.siegfried.ch/insights/tag/oral-solid-dosage-form) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Scale-up](https://content.siegfried.ch/insights/tag/scale-up) NEW 08/19/2026 [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) ### More than compliance: Managing the challenges of controlled substance manufacturing [Read article](https://content.siegfried.ch/insights/more-than-compliance-managing-the-challenges-of-controlled-substance-manufacturing) Recent #### [Jul 23, 2026 Scale-up Drug Products Dosage form scale-up: Balancing speed and efficiency in later-stage development](https://content.siegfried.ch/insights/dosage-form-scale-up-balancing-speed-and-efficiency-in-later-stage-development) #### [Jul 8, 2026 Early-phase development Regulatory support Navigating the complex route to regulatory compliance, from preclinical to market](https://content.siegfried.ch/insights/navigating-the-complex-route-to-regulatory-compliance-from-preclinical-to-market) #### [Jun 22, 2026 Scale-up Drug Products The need for speed: Early-stage dosage form development](https://content.siegfried.ch/insights/the-need-for-speed-early-stage-dosage-form-development) #### Subscribe for more expert insights   All posts ### [Aug 19, 2026 Early-phase development Regulatory support More than compliance: Managing the challenges of controlled substance manufacturing](https://content.siegfried.ch/insights/more-than-compliance-managing-the-challenges-of-controlled-substance-manufacturing) ### [Jul 23, 2026 Scale-up Drug Products Oral solid dosage form Dosage form scale-up: Balancing speed and efficiency in later-stage development](https://content.siegfried.ch/insights/dosage-form-scale-up-balancing-speed-and-efficiency-in-later-stage-development) ### [Jul 8, 2026 Early-phase development Regulatory support Navigating the complex route to regulatory compliance, from preclinical to market](https://content.siegfried.ch/insights/navigating-the-complex-route-to-regulatory-compliance-from-preclinical-to-market) ### [Jun 22, 2026 Scale-up Drug Products Oral solid dosage form The need for speed: Early-stage dosage form development](https://content.siegfried.ch/insights/the-need-for-speed-early-stage-dosage-form-development) ### [Apr 2, 2026 Accelerate to win: The challenges of dosage form development](https://content.siegfried.ch/insights/accelerate-to-win-the-challenges-of-dosage-form-development) ### [Mar 23, 2026 From lab to launch: Cutting time in pharmaceutical development](https://content.siegfried.ch/insights/from-lab-to-launch-cutting-time-in-pharmaceutical-development) [1](https://content.siegfried.ch/insights?page=1) [2](https://content.siegfried.ch/insights?page=2) [3](https://content.siegfried.ch/insights?page=3) [4](https://content.siegfried.ch/insights?page=4) [5](https://content.siegfried.ch/insights?page=5) Oct 30, 2025 ### Video: Insights from Chief Scientific Officer Stefan Randl at CPHI Frankfurt 2025 Sign up to stay up to date on Siegfried and our business performance. expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/) ```json { "@context" : "https://schema.org", "@type" : "VideoObject", "contentUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4", "dateModified" : "2025-10-31T17:20:09.538Z", "duration" : "PT2M16S", "height" : 1080, "name" : "Peter - Video 01 Final v2", "thumbnailUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4/medium.jpg", "uploadDate" : "2025-10-28T21:59:19.239Z", "width" : 1920 } ```